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KNOWLEDGE VALORIZATION  
In this chapter, the possibilities of valorization of the results presented in this thesis will be 
described. Valorization of research is the process of creating value from knowledge1. In other 
words, how can the obtained knowledge from this research be of relevance for the society in 
general, and how it can be (clinically) implemented?  
 
Societal and/or economic relevance 
The prevalence of age-related diseases, such as dementia, increases as a function of the 
growing aging population and an increased recognition and attention of its signs and 
symptoms from the public, sciences, practitioners and care providers2. An estimated 
254.000 individuals in the Netherlands met diagnostic criteria for dementia in 2015, and 
this number is expected to triple by 20503. This makes dementia for many high-income 
countries, among which the Netherlands, a health- and social-care priority3.  
In addition to the well-known cognitive impairments part of Alzheimer’s disease 
(AD), it is now acknowledged that nearly all patients with AD develop one or more 
neuropsychiatric symptoms (NPS) over the course of the disease4, 5. The implications of AD, 
and NPS in particular, are multifold. For one, there are direct consequences for the person 
with AD and his or her caregiver(s), in terms of high distress, increased burden, and lower 
quality of life (QoL)6, 7. An indication of the impact of NPS can be drawn from the finding 
that presence of NPS are a major determinant of (earlier) nursing home placement, leading 
to high long term institutionalization costs8. In fact, the societal costs of NPS in dementia are 
staggering: a third of dementia care costs has been attributed to the direct management of 
NPS, because of the greater use of health services, acute and respite hospitalization, and 
medication costs8-10. Additional costs are for example due to time spend by caregivers 
supervising the patient, which is time spent away from work or leisure activities11. These 
increased costs of dementia care are even significant in mild cognitive impaired community 
dwelling people11. Thus, NPS have a significant impact on patient and society, in terms of 
burden and costs.  
As there is no cure or disease-modifying treatment available for AD, one major goal is 
to increase and maintain QoL, for example by prevention and management of NPS. 
However, the multifactorial and heterogeneous nature of NPS makes this challenging. It is 
therefore necessary to increase our understanding of the underlying mechanisms of the 
development of NPS. More knowledge on the ideopathogenesis of NPS has implications for 
treatment development, as different patients with different NPS might benefit from different 
treatment strategies. Indeed, it was shown that AD pathology was cross-sectionally 
associated with anxiety and apathy (albeit indirectly, via disease severity) and with the 
development of depression and apathy over time, but not with symptoms such as agitation 
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and irritability. Although the research designs do not allow for differentiation between 
cause-and-effect, all studies showed that NPS are very common across the disease spectrum. 
Knowledge and acknowledgement of the high prevalence of NPS may result in better 
recognition, distinction and earlier detection of NPS. It also further underlines the 
importance of NPS, next to cognitive decline, as hallmarks of AD, even in prodromal phases 
of the disease.  
 
Target groups 
Mrs. J. is a 76-year old woman with mild AD dementia. A year after her first visit to the 
memory clinic, she is brought again by her daughter, because of concerns about behavioral 
changes. Her daughter mentions her decline in interest and sad mood: “Whereas she used 
to enjoy helping my father with household chores, she now sits in the living room and 
watches tv. She doesn’t even seem to enjoy visits from the grandchildren.” Mrs. J. smiles 
appropriately in social situations but does not further engage in conversations or other 
activities. Although the daughter is worried about her mother and demands further 
medical assessment, her father feels that as long Mrs. J. seems content, he should respect 
her decisions to no longer participate in daily activities.  
 
Various hypotheses have been posed to explain NPS in AD. It has been suggested that NPS 
are risk factors for AD or that NPS non-cognitive symptoms of the disease, which implies 
that NPS should be associated with underlying AD pathology2. The results of this thesis 
suggest that Mrs. J’s. development of symptoms of apathy experienced by Mrs. J. are (partly) 
explained by AD pathology.  
Knowledge on the relationship between AD pathology and NPS is in the first place of 
relevance for patients, caregivers, and clinicians. Even when not (yet) apparent, it would be 
beneficial to educate patient and caregivers that NPS are also considered symptoms of the 
disease. Oftentimes, NPS are not mentioned spontaneously by patient and caregiver, such 
that raising awareness of such symptoms will lead to earlier detection and recognition, in 
turn leading to earlier possibilities of interventions. One can think of modifiable factors 
other than neurobiology such as unmet needs (where a patient has lack of meaningful 
activities), factors related to caregiver (negative communication styles), or the environment 
(lowered stress threshold, difficulties with processing and responding to environmental 
stimuli). In the case study, the family of Mrs. J. might benefit from professional help to 
discuss strategies to encourage increased activity. Further, the frustration of Mrs. J.s 
daughter might be lessened if she is educated about the nature of apathy as part of the 
disease.  
The findings of this thesis are of relevance to health-care professionals as the burden 
of interpreting clinical and biomarker data rests with them. Perhaps it is not only the patient 
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and caregiver that should be educated about NPS, but also clinicians. In the presence of AD 
pathology, increased attention must be given to individualized care options as these patients 
are at risk for developing NPS. Prior studies showed that the presence of NPS is related to 
faster progression of the disease, which raises the interesting hypothesis that treatment or 
management of these symptoms can act as a protective factor for disease progression. The 
studies in this thesis further showed that the trajectories which individual NPS take are 
heterogeneous, underlining that cross-sectional assessment of affective symptoms is 
insufficient. In a like manner, it was shown that QoL does not follow a monotonic trajectory 
over time. That is, QoL increased after first visit to the memory clinic, after which it showed 
a decline. It is thus important that clinicians give continuous attention to QoL, even in light 
of first improvements.  
The findings are also of relevance for policy makers and care managers. In the 
Netherlands, the majority of people with dementia live at home, i.e. are “community-
dwelling”3, 12, which is also promoted by the government via the “Long-term Care Act” (Wet 
Langdurige Zorg, 2015). This has resulted in various legal frameworks involved with the 
organization and financing of dementia care, and thus many health care professionals are 
involved. Although the Dutch Elderly Care Physician guidelines for NPS in dementia13 
recommend the multidisciplinary analysis of NPS, the fragmentation of primary dementia 
care (and thus involving many health care professionals) does not facilitate coordinated care 
planning. Thus, it must be emphasized that once NPS have been identified, health care 
professionals must act together and communicate in order to manage them. 
The findings of this thesis provide a framework for researchers in the AD-NPS field. 
The large heterogeneity observed in prior studies with regard to measurement instruments 
and definitions suggests that AD-NPS research would likely benefit from uniform 
definitions. One such framework is the recently proposed AT(N) classification system, where 
patients are scored according to three biomarker categories14. It is not meant as a (clinical) 
diagnostic system but as a descriptive and standardized system, agnostic to temporal 
ordering of underlying mechanisms14. However, in the current phase of exploring NPS as an 
expression or cause of the disease, it is crucial to understand how individual biomarkers 
evolve over time and interact with each other or NPS. One must be aware of the 
consequences of utilizing arbitrary cut-offs in such research phase. Another implication of 
this thesis is the identification of the heterogeneity of study designs, instruments and 
definitions used. More effort must be made to reach consensus on definitions of the concepts 
under examination.  
For pharmaceutical companies who aim to find treatment strategies, this research is 
of relevance as it suggests that patients with more AD pathology are most likely to develop 
NPS over time. This means that inclusion criteria can be employed for such clinical trials, 
selecting those with lower amyloid and higher tau levels. However, this thesis also shows 
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that, in order to answer any question on causality, we need to extend the amount of 
measurements on NPS and biomarkers. That is, more frequent follow-up measurements on 
both parameters would allow modeling of the two in a parallel manner. We also need better 
characterizations of the psychiatry history of patients, such that in parallel to retrospective 
self-reports, we use data that is stored with the general practitioner.   
 
Innovation and products 
Throughout this thesis, we tried to step away from the thought that estimating one 
population-average approximates the truth. In the first part of this thesis a comprehensive 
state-of-the-art view on the association between AD biomarkers and NPS was offered. By 
combining information from all relevant studies, the systematic review and meta-analysis 
can provide more precise estimates of the effects than those derived from individual 
studies15. This also allowed the generation of hypotheses that were tested in following 
chapters, for example, regarding differential effects along the AD disease spectrum. In 
addition, the nature and relative strength of the associations between AD biomarkers and 
NPS were explored more in-depth by including cross-sectional mediation analyses. Further, 
we utilized an innovative statistical technique by which subjects could be grouped into latent 
classes on the basis of similarities in their trajectories over time. Following the line of 
reasoning from personalized medicine - where diagnosis and treatment is based on 
individual characteristics - , we should aim to conduct research in such way that we are able 
to incorporate multiple indicators and zoom in on an individual level. The main product of 
this thesis is the implication of the results for clinical practice and future research, as 
described above. Finally, the collection, cleaning and harmonization of multi-center data 
done for this thesis (and documentation thereof) will allow future researchers to utilize these 
beautiful datasets.  
 
Schedule and implementation 
A large part of the results of this research has been disseminated via publications in 
international, peer-reviewed, scientific journals and presentations at international 
conferences. The results have implications for our ongoing research, where we continue the 
examination of the association of AD pathology with behavioral changes, for example in the 
concept of mild behavioral impairment (MBI16), in collaboration with the Johns Hopkins 
University School of Medicine research group at the department of Psychiatry and 
Behavioral Sciences, Division of Geriatric Psychiatry and Neuropsychiatry. Further, we aim 
to expand the examination of trajectories of individual NPS, for example by including 
interactions with other NPS.  
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